{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:20:34Z","timestamp":1793762434483,"version":"4.6.1"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Anthracyclines can improve survival in many types of malignancies, but\ndose-dependent and irreversible results following the use of anthracyclines have been associated\nwith cardiomyopathy. This meta-analysis aimed to compare the effects of prophylactic agents for\npreventing cardiotoxicity induced following anticancer agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In this meta-analysis, Scopus, Web of Science, and PubMed were surfed for articles\npublished by December 30th, 2020. The keywords were angiotensin\u2010converting enzyme inhibitor\n(ACEI), enalapril, captopril, angiotensin receptor blocker, beta blocker, metoprolol, bisoprolol,\nisoprolol, statin, valsartan, losartan, eplerenone, idarubicin, nebivolol, dihydromyricetin, ampelopsin,\nspironolactone, dexrazoxane, antioxidants, cardiotoxicity, n-acetyl-tryptamine, cancer, neoplasms,\nchemotherapy, anthracyclines, doxorubicin, daunorubicin, epirubicin, idarubicin, ejection fraction or a\ncombination of them in the titles or abstracts.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 17 articles out of 728 studies examining 2,674 patients were included in this\nsystematic review and meta-analysis. Ejection fraction (EF) values in the baseline, 6-month, and\n12-month follow-up in the intervention group turned out to be 62.52 \u00b1 2.48, 59.63 \u00b1 4.85, and\n59.42 \u00b1 4.53, whereas in the control group appeared to be 62.81 \u00b1 2.58, 57.69 \u00b1 4.32, and 58.60 \u00b1\n4.58, respectively. Through comparison of the two groups, EF was found to increase in the\nintervention group by 0.40 after 6 months (Standardized mean difference (SMD): 0.40, 95%\nconfidence interval (CI): 0.27, 0.54), thus proving higher than that of the control groups\nfollowing the cardiac drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This meta-analysis showed that prophylactic treatment with cardio-protective drugs,\nincluding dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with\nanthracycline, have a protective effect on LVEF and prevent EF drop.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574887118666230118102252","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:52:01Z","timestamp":1674042721000},"page":"112-122","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prophylactic Agents for Preventing Cardiotoxicity Induced Following\nAnticancer Agents: A Systematic Review and Meta-Analysis of Clinical\nTrials"],"prefix":"10.2174","volume":"18","author":[{"given":"Seyed Mohammad","family":"Amin Hashemipour","sequence":"first","affiliation":[{"name":"Young Researchers and Elites Club, Faculty of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohollah","family":"Valizadeh","sequence":"first","affiliation":[{"name":"Urmia\nUniversity of Medical Sciences, Urmia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Keshavarzian","sequence":"additional","affiliation":[{"name":"Health Care Center of Karun, Ahwaz Jondishapur University of Medical Science, Ahwaz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tella","family":"Sadighpour","sequence":"additional","affiliation":[{"name":"Herbert Wertheim\nCollege of Medicine, Florida International University, Florida, FL, 33199, USA"},{"name":"American University of Antigua College of\nMedicine, Osbourn, Antigua &amp; Barbuda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammadreza","family":"Mortazavizadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yazd Branch, Islamic Azad University,\nYazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadhossein","family":"Soltani","sequence":"additional","affiliation":[{"name":"Cardiologist, Fellowship of Heart Failure, Yazd Cardiovascular Research Center, Shahid Sadoughi\nUniversity of Medical Sciences, Yazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Farzin","family":"Motevalipoor","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Yazd branch, Islamic Azad University, Yazd,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriyar Shahbazi","family":"Khamas","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Moazen","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics\nand Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kogani","sequence":"additional","affiliation":[{"name":"Research Center for Environmental Contaminants (RCEC), Abadan University of Medical Sciences, Abadan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Hosseinpour","sequence":"additional","affiliation":[{"name":"Urmia\nUniversity of Medical Sciences, Urmia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"Jemal A.","year":"2011","unstructured":"Jemal A.; Bray F.; Center M.M.; Ferlay J.; Ward E.; Forman D.; Global cancer statistics. CA Cancer J Clin 2011,61(2),69-90","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ejca.2008.11.018","volume":"45","author":"Sant M.","year":"2009","unstructured":"Sant M.; Allemani C.; Santaquilani M.; Knijn A.; Marchesi F.; Capocaccia R.; EUROCARE-4. survival of cancer patients diagnosed in 1995\u20131999. Results and commentary. Eur J Cancer 2009,45(6),931-991","journal-title":"Eur J Cancer"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"Minotti G.","year":"2004","unstructured":"Minotti G.; Menna P.; Salvatorelli E.; Cairo G.; Gianni L.; Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004,56(2),185-229","journal-title":"Pharmacol Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"Swain S.M.","year":"2003","unstructured":"Swain S.M.; Whaley F.S.; Ewer M.S.; Congestive heart failure in patients treated with doxorubicin. Cancer 2003,97(11),2869-2879","journal-title":"Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"Henriksen P.A.","year":"2018","unstructured":"Henriksen P.A.; Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention. Heart 2018,104(12),971-977","journal-title":"Heart"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s12350-016-0538-8","volume":"23","author":"Russell R.R.","year":"2016","unstructured":"Russell R.R.; Alexander J.; Jain D.; The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol 2016,23(4),856-884","journal-title":"J Nucl Cardiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11897-018-0400-1","volume":"15","author":"Sharalaya Z.","year":"2018","unstructured":"Sharalaya Z.; Collier P.; Prevention of cardiotoxicities with traditional and novel chemotherapeutic agents. Curr Heart Fail Rep 2018,15(4),260-269","journal-title":"Curr Heart Fail Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"Cardinale D.","year":"2020","unstructured":"Cardinale D.; Iacopo F.; Cipolla C.M.; Cardiotoxicity of anthracyclines. Front Cardiovasc Med 2020,7,26","journal-title":"Front Cardiovasc Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"Volkova M.","year":"2012","unstructured":"Volkova M.; Russell R.; Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Curr Cardiol Rev 2012,7(4),214-220","journal-title":"Curr Cardiol Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjh.15603","volume":"183","author":"Baech J.","year":"2018","unstructured":"Baech J.; Hansen S.M.; Lund P.E.; Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol 2018,183(5),717-726","journal-title":"Br J Haematol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"Steinherz L.J.","year":"1991","unstructured":"Steinherz L.J.; Steinherz P.G.; Tan C.T.; Heller G.; Murphy M.L.; Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991,266(12),1672-1677","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/med.21280","volume":"34","author":"Carvalho F.S.","year":"2014","unstructured":"Carvalho F.S.; Burgeiro A.; Garcia R.; Moreno A.J.; Carvalho R.A.; Oliveira P.J.; Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 2014,34(1),106-135","journal-title":"Med Res Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"Varricchi G.","year":"2018","unstructured":"Varricchi G.; Ameri P.; Cadeddu C.; Antineoplastic drug-induced cardiotoxicity: A redox perspective. Front Physiol 2018,9,167","journal-title":"Front Physiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1291\/hypres.25.597","volume":"25","author":"Toko H.","year":"2002","unstructured":"Toko H.; Oka T.; Zou Y.; Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002,25(4),597-603","journal-title":"Hypertens Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1542\/peds.2007-0575","volume":"121","author":"Shankar S.M.","year":"2008","unstructured":"Shankar S.M.; Marina N.; Hudson M.M.; Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the children\u2019s oncology group. Pediatrics 2008,121(2),e387-e396","journal-title":"Pediatrics"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"Von Hoff D.D.","year":"1979","unstructured":"Von Hoff D.D.; Layard M.W.; Basa P.; Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979,91(5),710-717","journal-title":"Ann Intern Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/0003-4819-106-6-814","volume":"106","author":"Saini J.","year":"1987","unstructured":"Saini J.; Rich M.W.; Lyss A.P.; Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987,106(6),814-816","journal-title":"Ann Intern Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.ihj.2018.06.011","volume":"70","author":"Abuosa A.M.","year":"2018","unstructured":"Abuosa A.M.; Elshiekh A.H.; Qureshi K.; Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Indian Heart J 2018,70(S3),S96-s100","journal-title":"Indian Heart J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cjca.2018.11.028","volume":"35","author":"Calvillo-Arg\u00fcelles O.","year":"2019","unstructured":"Calvillo-Arg\u00fcelles O.; Abdel-Qadir H.; Michalowska M.; Cardioprotective effect of statins in patients with her2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol 2019,35(2),153-159","journal-title":"Can J Cardiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"Bhagat A.","year":"2020","unstructured":"Bhagat A.; Kleinerman E.S.; Anthracycline-induced cardiotoxicity: Causes, mechanisms, and prevention. Adv Exp Med Biol 2020,1257,181-192","journal-title":"Adv Exp Med Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4048\/jbc.2017.20.1.82","volume":"20","author":"Kim I.H.","year":"2017","unstructured":"Kim I.H.; Lee J.E.; Youn H.J.; Song B.J.; Chae B.J.; Cardioprotective effect of dexrazoxane in patients with her2-positive breast cancer who receive anthracycline based adjuvant chemotherapy followed by trastuzumab. J Breast Cancer 2017,20(1),82-90","journal-title":"J Breast Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"Barron T.I.","year":"2011","unstructured":"Barron T.I.; Connolly R.M.; Sharp L.; Bennett K.; Visvanathan K.; Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol 2011,29(19),2635-2644","journal-title":"J Clin Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.yjmcc.2011.06.019","volume":"51","author":"Fajardo G.","year":"2011","unstructured":"Fajardo G.; Zhao M.; Berry G.; Wong L.J.; Mochly-Rosen D.; Bernstein D.; \u03b22-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways. J Mol Cell Cardiol 2011,51(5),781-789","journal-title":"J Mol Cell Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"Gujral D.M.","year":"2018","unstructured":"Gujral D.M.; Lloyd G.; Bhattacharyya S.; Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction and heart failure during anthracycline chemotherapy \u00b1 trastuzumab. Breast 2018,37,64-71","journal-title":"Breast"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.amjcard.2018.08.039","volume":"122","author":"Kheiri B.","year":"2018","unstructured":"Kheiri B.; Abdalla A.; Osman M.; Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity. Am J Cardiol 2018,122(11),1959-1964","journal-title":"Am J Cardiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D.","year":"2009","unstructured":"Moher D.; Liberati A.; Tetzlaff J.; Altman D.G.; Group P.; Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009,6(7),e1000097","journal-title":"PLoS Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"Jadad A.R.","year":"1996","unstructured":"Jadad A.R.; Moore R.A.; Carroll D.; Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996,17(1),1-12","journal-title":"Control Clin Trials"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","volume":"357","author":"Moher D.","year":"2001","unstructured":"Moher D.; Schulz K.F.; Altman D.G.; The CONSORT statement: Tevised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001,357(9263),1191-1194","journal-title":"Lancet"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10549-009-0730-5","volume":"122","author":"Blaes A.H.","year":"2010","unstructured":"Blaes A.H.; Gaillard P.; Peterson B.A.; Yee D.; Virnig B.; Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat 2010,122(2),585-590","journal-title":"Breast Cancer Res Treat"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2147\/CMAR.S166481","volume":"10","author":"Cochera F.","year":"2018","unstructured":"Cochera F.; Dinca D.; Bordejevic D.A.; Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. Cancer Manag Res 2018,10,2071-2081","journal-title":"Cancer Manag Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","volume":"21","author":"Elitok A.","year":"2014","unstructured":"Elitok A.; Oz F.; Cizgici A.Y.; Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol J 2014,21(5),509-515","journal-title":"Cardiol J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"Gupta V.","year":"2018","unstructured":"Gupta V.; Kumar Singh S.; Agrawal V.; Bali Singh T.; Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer 2018,65(11),e27308","journal-title":"Pediatr Blood Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"Janbabai G.","year":"2017","unstructured":"Janbabai G.; Nabati M.; Faghihinia M.; Azizi S.; Borhani S.; Yazdani J.; Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol 2017,17(2),130-139","journal-title":"Cardiovasc Toxicol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","volume":"15","author":"Swain S.M.","year":"1997","unstructured":"Swain S.M.; Whaley F.S.; Gerber M.C.; Ewer M.S.; Bianchine J.R.; Gams R.A.; Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997,15(4),1333-1340","journal-title":"J Clin Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","volume":"134","author":"Tashakori Beheshti A.","year":"2016","unstructured":"Tashakori Beheshti A.; Mostafavi Toroghi H.; Hosseini G.; Zarifian A.; Homaei Shandiz F.; Fazlinezhad A.; Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: A double-blind randomized trial. Cardiology 2016,134(1),47-53","journal-title":"Cardiology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12872-016-0364-6","volume":"16","author":"Armenian S.H.","year":"2016","unstructured":"Armenian S.H.; Hudson M.M.; Chen M.H.; Rationale and design of the Children\u2019s Oncology Group (COG) study ALTE1621: A randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovasc Disord 2016,16(1),187","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","volume":"60","author":"Seicean S.","year":"2012","unstructured":"Seicean S.; Seicean A.; Plana J.C.; Budd G.T.; Marwick T.H.; Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study. J Am Coll Cardiol 2012,60(23),2384-2390","journal-title":"J Am Coll Cardiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.33963\/KP.15163","volume":"78","author":"S\u0142owik A.","year":"2020","unstructured":"S\u0142owik A.; Jagielski P.; Potocki P.; Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: Results of a prospective randomized study. Kardiol Pol 2020,78(2),131-137","journal-title":"Kardiol Pol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"Cardinale D.","year":"2018","unstructured":"Cardinale D.; Ciceri F.; Latini R.; Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The international cardiooncology society-one trial. Eur J Cancer 2018,94,126-137","journal-title":"Eur J Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4070\/kcj.2013.43.3.174","volume":"43","author":"Jo S.H.","year":"2013","unstructured":"Jo S.H.; Kim L.S.; Kim S.A.; Evaluation of short-term use of n-acetylcysteine as a strategy for prevention of anthracycline-induced cardiomyopathy: epoch trial - a prospective randomized study. Korean Circ J 2013,43(3),174-181","journal-title":"Korean Circ J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1200\/JCO.1998.16.1.86","volume":"16","author":"Lopez M.","year":"1998","unstructured":"Lopez M.; Vici P.; Di L.K.; Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998,16(1),86-92","journal-title":"J Clin Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/08880019709009491","volume":"14","author":"Schiavetti A.","year":"1997","unstructured":"Schiavetti A.; Castello M.A.; Versacci P.; Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: Preliminary results. Pediatr Hematol Oncol 1997,14(3),213-222","journal-title":"Pediatr Hematol Oncol"},{"key":"ref=43","first-page":"772","volume":"55","author":"Abdali F.","year":"2017","unstructured":"Abdali F.; Taghavi S.; Vazifekhah S.; Naghavi B.M.; Mirza A.A.M.; Effect of progesterone on latent phase prolongation in patients with preterm premature rupture of membranes. Acta Med Iran 2017,55(12),772-778","journal-title":"Acta Med Iran"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12012-019-09558-1","volume":"20","author":"Xu L.","year":"2020","unstructured":"Xu L.; Long Y.; Tang X.; Zhang N.; Cardioprotective effects and duration of beta blocker therapy in anthracycline-treated patients: A systematic review and meta-analysis. Cardiovasc Toxicol 2020,20(1),11-19","journal-title":"Cardiovasc Toxicol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1006\/taap.2002.9532","volume":"185","author":"Santos D.","year":"2002","unstructured":"Santos D.; Moreno A.J.; Leino R.L.; Froberg M.K.; Wallace K.B.; Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002,185(3),218-227","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","volume":"91","author":"Yun S.","year":"2015","unstructured":"Yun S.; Vincelette N.D.; Abraham I.; Cardioprotective role of \u03b2-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: A systematic review and meta-analysis. Postgrad Med J 2015,91(1081),627-633","journal-title":"Postgrad Med J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/djn014","volume":"100","author":"Chapman J.A.W.","year":"2008","unstructured":"Chapman J.A.W.; Meng D.; Shepherd L.; Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008,100(4),252-260","journal-title":"J Natl Cancer Inst"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1200\/JCO.1984.2.2.112","volume":"2","author":"Ewer M.S.","year":"1984","unstructured":"Ewer M.S.; Ali M.K.; Mackay B.; A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol 1984,2(2),112-117","journal-title":"J Clin Oncol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"Lewinter C.","year":"2022","unstructured":"Lewinter C.; Nielsen T.H.; Edfors L.A.; A systematic review and meta-analysis of beta-blockers and renin\u2013angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J 2022,43(27),2562-2569","journal-title":"Eur Heart J"}],"container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574887118666230118102252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212845\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574887118666230118102252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:02:29Z","timestamp":1690182149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212845\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574887118666230118102252","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}